1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)
暂无分享,去创建一个
R. Laing | L. Fehrenbacher | R. Roylance | K. Petráková | P. Vuylsteke | M. Huizing | S. Singel | F. Abell | D. Apt | J. Zhou | S. Chan